ARS Pharmaceuticals, Inc. (SPRY) Tops Q3 EPS by 2c

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q3 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18).

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)